Stocks Health care AEON
NYSE · Health careAEON Biopharma, Inc. (AEON)
It posted a net loss of $54.6M. In fiscal 2025 capital spending exceeded operating cash flow by $17.3M. At June 30, 2026 it held $3.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
What AEON Biopharma, Inc. does
AEON Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker AEON.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$39.2M | -$3.95 | -$17.3M |
| 2024 | n/a | $42M | $72.93 | n/a |
| 2022 | n/a | -$52.6M | -$0.38 | -$35.9M |
| 2021 | n/a | $8.2M | n/a | n/a |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What AEON Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 21, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026
- August 12, 2026
- August 3, 2026
- July 23, 2026Other event 8-K
- July 21, 2026Passive stake (5% or more) SCHEDULE 13G
- July 15, 2026
- July 15, 2026
- July 13, 2026Form S-1MEF filing S-1MEF
- July 9, 2026
Insider trades
What the people running AEON Biopharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $243.5K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 19, 2026 | Lynch Timothy P10% owner | Bought | 1,150,000 | $243.5K |
| June 17, 2026 | Carter Eric GDirector | Received as pay | 222,684 | - |
| June 17, 2026 | Fischer JostDirector | Received as pay | 222,684 | - |
| June 17, 2026 | Forth MarcDirector | Received as pay | 222,684 | - |
| June 17, 2026 | Palmisano Robert JDirector | Received as pay | 222,684 | - |
| June 17, 2026 | Thunen Shelley BDirector | Received as pay | 222,684 | - |
Who owns AEON
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Daewoong Co.,Ltd. ("DWC")13D, may seek influence with 1 related filers | 49.99% | January 29, 2026 |
| Timothy P. Lynch13G, passive | 13% | August 21, 2026 |
| Chernett Jorey13G, passive | 9.9% | May 30, 2025 |
| Stonepine Capital Management, LLC13G, passive with 3 related filers | 9.9% | July 21, 2026 |
| Dauntless Investment Group, LLC13G, passive | 9.7% | March 3, 2025 |
| Bigger Michael13G, passive with 6 related filers | 6.1% | January 8, 2025 |
| Robert J Palmisano13D, may seek influence with 1 related filers | 5.7% | March 7, 2025 |
Largest institutional holders
Insiders
6 insiders reported holding 8,738,815 shares in total, about $2.3M at the last price.
| Holder | Shares |
|---|---|
| Lynch Timothy P10% owner | 6,500,000 |
| Forth MarcDirector | 973,231 |
| Fischer JostDirector | 489,469 |
| Palmisano Robert JDirector | 258,705 |
| Thunen Shelley BDirector | 258,705 |
| Carter Eric GDirector | 258,705 |
Questions about AEON
What does AEON Biopharma, Inc. do?
AEON Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker AEON.
Is AEON Biopharma, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $54.6M.
When did AEON Biopharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from August 21, 2026.
Similar companies
Compare AEON with
Follow AEON
Get an email when AEON Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow AEON: get an email when it filesWhere the numbers come from
Financial figures are the values AEON Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.